PharmAla Named Exclusive MDMA Supplier to Revive Therapeutics
February 06, 2023 08:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 06, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) is pleased to announce that it has signed on to act as exclusive supplier of...
Australia Allows Prescription of MDMA and Psilocybin in Groundbreaking Regulatory Change
February 03, 2023 00:01 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Feb. 03, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA) applauds the Australian Therapeutic Goods Administration (TGA) in allowing for...
PharmAla Biotech granted an Export Permit for 300 grams of LaNeo™ MDMA
January 24, 2023 08:50 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Jan. 24, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA), a biotechnology company focused on the research, development, and...
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
November 16, 2022 07:30 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”)(CSE: MDMA), a biotechnology company focused on the research, development, and manufacturing...
PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA
November 02, 2022 09:00 ET
|
PharmAla Biotech
VANCOUVER, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- PharmAla Biotech (CSE:MDMA) is pleased to announce that it has submitted its pre-IND data meeting package to the US Food and Drug...